Granules India is currently trading at Rs. 322.50, up by 7.60 points or 2.41% from its previous closing of Rs. 314.90 on the BSE.
The scrip opened at Rs. 319.50 and has touched a high and low of Rs. 324.70 and Rs. 319.50 respectively.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 335.90 on 10-Aug-2020 and a 52 week low of Rs. 86.70 on 26-Aug-2019.
Last one week high and low of the scrip stood at Rs. 324.70 and Rs. 302.50 respectively. The current market cap of the company is Rs. 7793.99 crore.
The promoters holding in the company stood at 42.13%, while Institutions and Non-Institutions held 26.16% and 31.71% respectively.
The US Food & Drug Administration (USFDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules Pharmaceuticals, Inc (GPI), a wholly owned foreign subsidiary of Granules India for Ramelteon Tablets, 8 mg. It is bioequivalent to the reference listed drug product (RLD), Rozerem Tablets, 8 mg, of Takeda Pharmaceuticals U.S.A., Inc. Ramelteon Tablets are used for the treatment of insomnia characterized by difficulty with sleep onset.
Granules now has a total of 29 ANDA approvals from US FDA (27 Final approvals and 2 tentative approvals). Ramelteon Tablets had U.S. sales of approximately $33 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health.
Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).
